Moreover, in nonalcoholic fatty liver disease (NAFLD) subjects, there is an important liver biomarker improvement (expressed as ALT and AST activity) following efficient periodontal therapy. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.